Biohaven Ltd
BHVN17.390USD
-0.720-3.98%
終値 10/30, 16:00（ET）15分遅れの株価
1.84B時価総額
損失額直近12ヶ月PER
詳細情報 Biohaven Ltd 企業名
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; Transient Receptor Potential Melastatin 3 (TRPM3) antagonism for migraine and neuropathic pain; Tyrosine Kinase 2/Janus Kinase 1 (TYK2/JAK1) inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates (ADCs) for cancer. The Troriluzole is a new chemical entity (NCE) and tripeptide prodrug of the active metabolite, riluzole.
Biohaven Ltdの企業情報
企業コードBHVN
会社名Biohaven Ltd
上場日Sep 23, 2022
最高経営責任者「CEO」Dr. Vlad Coric, M.D.
従業員数256
証券種類Ordinary Share
決算期末Sep 23
本社所在地215 Church Street
都市NEW HAVEN
証券取引所NYSE Consolidated
国United States of America
郵便番号06510
電話番号12034040410
ウェブサイトhttps://www.biohaven.com/
企業コードBHVN
上場日Sep 23, 2022
最高経営責任者「CEO」Dr. Vlad Coric, M.D.
Biohaven Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Director
Director
22.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
Mr. Robert J. Hugin
Mr. Robert J. Hugin
Independent Director
Independent Director
12.96K
--
Dr. Irina Antonijevic, M.D., Ph.D.
Dr. Irina Antonijevic, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. John W. Childs
Mr. John W. Childs
Independent Director
Independent Director
--
--
Dr. Vlad Coric, M.D.
Dr. Vlad Coric, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Gregory Hugh (Greg) Bailey, M.D.
Dr. Gregory Hugh (Greg) Bailey, M.D.
Independent Director
Independent Director
1.62M
--
Mr. Matthew (Matt) Buten
Mr. Matthew (Matt) Buten
Chief Financial Officer
Chief Financial Officer
193.45K
+0.39%
Dr. Bruce Car, Ph.D.
Dr. Bruce Car, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
34.80K
+757.19%
Ms. Julia Paige Gregory
Ms. Julia Paige Gregory
Independent Director
Independent Director
25.66K
--
Mr. Kishan (Kishen) Mehta
Mr. Kishan (Kishen) Mehta
Director
Director
22.66K
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Lead Independent Director
Lead Independent Director
15.18K
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sat, Aug 16
更新時刻: Sat, Aug 16
株主統計
種類
株主統計
株主統計
比率
1919 Investment Counsel, LLC
6.23%
Childs John W
6.15%
BlackRock Institutional Trust Company, N.A.
6.08%
Suvretta Capital Management, LLC
5.31%
Janus Henderson Investors
4.78%
他の
71.44%
株主統計
株主統計
比率
1919 Investment Counsel, LLC
6.23%
Childs John W
6.15%
BlackRock Institutional Trust Company, N.A.
6.08%
Suvretta Capital Management, LLC
5.31%
Janus Henderson Investors
4.78%
他の
71.44%
種類
株主統計
比率
Investment Advisor
28.64%
Investment Advisor/Hedge Fund
25.57%
Hedge Fund
16.33%
Individual Investor
11.13%
Research Firm
3.53%
Venture Capital
1.11%
Sovereign Wealth Fund
0.85%
Corporation
0.48%
Pension Fund
0.46%
他の
11.89%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
557
87.60M
82.81%
-13.24M
2025Q2
561
102.09M
99.98%
-11.50M
2025Q1
573
104.91M
102.74%
-8.33M
2024Q4
560
105.43M
103.87%
-2.30M
2024Q3
544
99.41M
101.90%
-4.10M
2024Q2
514
95.57M
103.25%
+3.60M
2024Q1
494
86.58M
104.39%
-3.45M
2023Q4
444
83.44M
104.38%
+4.72M
2023Q3
398
73.50M
107.61%
-2.29M
2023Q2
372
72.49M
106.13%
-7.40M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
1919 Investment Counsel, LLC
6.60M
6.23%
+2.50K
+0.04%
Jun 30, 2025
Childs John W
6.51M
6.15%
+351.58K
+5.71%
Mar 10, 2025
BlackRock Institutional Trust Company, N.A.
6.44M
6.08%
+113.23K
+1.79%
Jun 30, 2025
Suvretta Capital Management, LLC
5.62M
5.31%
--
--
Jun 30, 2025
Janus Henderson Investors
5.05M
4.78%
-1.38M
-21.51%
Jun 30, 2025
State Street Investment Management (US)
3.54M
3.34%
+115.81K
+3.38%
Jun 30, 2025
Coric (Vladimir)
3.18M
3%
+26.57K
+0.84%
Mar 10, 2025
T. Rowe Price Associates, Inc.
3.08M
2.91%
+340.20K
+12.40%
Jun 30, 2025
The Vanguard Group, Inc.
9.23M
8.72%
+828.80K
+9.87%
Jun 30, 2025
Bellevue Asset Management AG
2.80M
2.65%
+762.00K
+37.34%
Jun 30, 2025
詳細を見る
関連ETF
更新時刻: Mon, Oct 6
更新時刻: Mon, Oct 6
銘柄名
比率
iShares Neuroscience and Healthcare ETF
2.95%
Roundhill GLP-1 & Weight Loss ETF
1.88%
Simplify Health Care ETF
1.12%
Virtus LifeSci Biotech Clinical Trials ETF
0.77%
SPDR S&P Biotech ETF
0.45%
WisdomTree BioRevolution Fund
0.31%
Direxion Daily S&P Biotech Bull 3X Shares
0.27%
Inspire Small/Mid Cap ESG ETF
0.2%
JPMorgan Fundamental Data Science Small Core ETF
0.18%
iShares Biotechnology ETF
0.13%
詳細を見る
iShares Neuroscience and Healthcare ETF
比率2.95%
Roundhill GLP-1 & Weight Loss ETF
比率1.88%
Simplify Health Care ETF
比率1.12%
Virtus LifeSci Biotech Clinical Trials ETF
比率0.77%
SPDR S&P Biotech ETF
比率0.45%
WisdomTree BioRevolution Fund
比率0.31%
Direxion Daily S&P Biotech Bull 3X Shares
比率0.27%
Inspire Small/Mid Cap ESG ETF
比率0.2%
JPMorgan Fundamental Data Science Small Core ETF
比率0.18%
iShares Biotechnology ETF
比率0.13%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
